Aligos Therapeutics (ALGS) Return on Sales (2021 - 2025)
Historic Return on Sales for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to 42.56%.
- Aligos Therapeutics' Return on Sales fell 271500.0% to 42.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 32.96%, marking a year-over-year decrease of 176200.0%. This contributed to the annual value of 36.34% for FY2024, which is 269500.0% down from last year.
- According to the latest figures from Q3 2025, Aligos Therapeutics' Return on Sales is 42.56%, which was down 271500.0% from 16.44% recorded in Q2 2025.
- In the past 5 years, Aligos Therapeutics' Return on Sales ranged from a high of 138.55% in Q1 2025 and a low of 135.56% during Q4 2024
- In the last 5 years, Aligos Therapeutics' Return on Sales had a median value of 13.88% in 2023 and averaged 18.76%.
- Its Return on Sales has fluctuated over the past 5 years, first crashed by -1216800bps in 2024, then soared by 1887800bps in 2025.
- Aligos Therapeutics' Return on Sales (Quarter) stood at 102.76% in 2021, then skyrocketed by 94bps to 6.19% in 2022, then tumbled by -124bps to 13.88% in 2023, then tumbled by -876bps to 135.56% in 2024, then soared by 69bps to 42.56% in 2025.
- Its last three reported values are 42.56% in Q3 2025, 16.44% for Q2 2025, and 138.55% during Q1 2025.